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Engineering Recombinant Orsay Virus Directly in the Metazoan Host
Caenorhabditis elegans
Hongbing Jiang, Carl J. Franz, David Wang
Departments of Molecular Microbiology and Pathology & Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA

The recent identification of Orsay virus, the first virus that is capable of naturally infecting Caenorhabditis elegans, provides a
unique opportunity to explore host-virus interaction studies in this invaluable model organism. A key feature of this system is
the robust genetic tractability of the host, C. elegans, which would ideally be complemented by the ability to genetically manipulate Orsay virus in parallel. To this end, we developed a plasmid-based reverse genetics system for Orsay virus by creating transgenic C. elegans strains harboring Orsay virus cDNAs. Both wild-type and mutant Orsay viruses, including a FLAG epitopetagged recombinant Orsay virus, were generated by use of the reverse genetics system. This is the first plasmid-based virus
reverse genetics system in the metazoan C. elegans. The Orsay virus reverse genetics we established will serve as a fundamental
tool in host-virus interaction studies in the model organism C. elegans.
IMPORTANCE

To date, Orsay virus is the first and the only identified virus capable of naturally infecting Caenorhabditis elegans. C. elegans is a
simple multicellular model organism that mimics many fundamental features of human biology and has been used to define
many biological properties conserved through evolution. Thus, the Orsay virus-C. elegans infection system provides a unique
opportunity to study host-virus interactions. In order to take maximal advantage of this system, the ability to genetically engineer mutant forms of Orsay virus would be highly desirable. Most efforts to engineer viruses have been done with cultured cells.
Here we describe the creation of mutant viruses directly in the multicellular organism C. elegans without the use of cell culture.
We engineered a virus expressing a genetically tagged protein that could be detected in C. elegans. This provides proof of concept
for modifying Orsay virus, which will greatly facilitate studies in this experimental system.

O

rsay virus, which was recently discovered in a wild Caenorhabditis elegans strain, is the only known virus capable of
naturally infecting the model organism C. elegans (1). Orsay virus
has a bipartite positive-sense RNA genome and is most closely
related to nodaviruses (1, 2). The Orsay virus RNA1 genome segment, which is ⬃3.4 kb in length, encodes an RNA-dependent
RNA polymerase (RdRP), while the Orsay virus RNA2 genome
segment, which is ⬃2.5 kb, encodes the viral capsid protein and a
novel capsid-delta fusion protein of unknown function that is
expressed by a ribosomal frameshifting mechanism (3).
As many fundamental biological discoveries have been made in
the C. elegans model, the ability of Orsay virus to infect C. elegans
provides a unique and powerful experimental system to define
multiple aspects of host-virus interactions. Prior to the discovery
of Orsay virus, only limited studies with C. elegans using a Flock
House virus replicon (4), vesicular stomatitis virus infection of
primary nematode cells (5, 6), or artificial infection of C. elegans
by vaccinia virus (7) have been reported. Those studies defined
antiviral roles for the RNA interference (RNAi) pathway and
apoptosis genes in C. elegans. To date, analysis of Orsay virus infection has confirmed a role for the RNAi pathway, and dicerrelated helicase 1 (drh-1) in particular, in antiviral defense in C.
elegans (8, 9). Additional efforts to define novel pathways of antiviral immunity using Orsay virus will capitalize on the robust host
genetics available in C. elegans. As most viruses encode proteins
that antagonize host antiviral defenses, it would be ideal if the
Orsay virus genome could be manipulated to identify such proteins. The Orsay-C. elegans system could also exploit another
unique property of C. elegans, its transparency, which could be
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leveraged to directly visualize Orsay virus infection and spread in
vivo, provided a suitable reporter virus (e.g., fluorescently tagged)
could be created. Furthermore, the ability to genetically define a
function for the novel capsid-delta fusion protein would be enhanced by creating mutant viruses that cannot express the capsiddelta fusion protein. Thus, engineering Orsay virus would greatly
enhance studies in the Orsay-C. elegans infection system.
For many viruses, reverse genetics have been developed in order to be able to create mutant viruses (10–15). Reverse genetics
systems for multiple nodaviruses, including Flock House virus,
Pariacoto virus, and a fish-infecting betanodavirus, have been described previously (16–20). In these examples, a viral cDNA construct driven by a T7 promoter is transfected into mammalian
cells that express a helper T7 polymerase. All of these systems rely
upon mammalian cell cultures for the generation of recombinant
virus. However, no cell culture system capable of propagating Orsay virus has been identified, and therefore, an alternative approach is required to develop reverse genetics for Orsay virus.
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ABSTRACT

Reverse Genetics for Orsay Virus in C. elegans

TABLE 1 Primers used in this study
Sequence (5=–3=)

HIPR1F1
HIPR1F2
RzRev1-1
RzRev1-2
RzRev2
RzRev3-1
HIPR2F
RzRev3-2
RNA1muX
R2MF
R2MR
R2FLAGF
HIPR2R

GAATGCGGGTATATAAGGAAAGCGGGCTCAGAGGAAGCCACAATTGTCGACTTGATACC
AATGCATCTAGGACCTTCTAGAACATTCTGTAAGGCTGCAGAATGCGGGTATATAAGG
AGGTCGGACCGCGAGGAGGTGGAGATGCCATGCCGACCCACCGTCCCGTGGG
AGGTCGGACCGCGAGGAGGTGGAGATGCCATGCCGACCCACGGCCAAAGAGGTTA
GGACGTGCGTCCTCCTTCGGATGCCCAGGTCGGACCGCGAG
TCCCGGGCCGCGGCTCCCTTAGCCATCCGAGTGGACGTGCGTCCTCC
GCTGCAGAATGCGGGTATATAAGGAAAGCGGGCTCAGAGGAAGCCTAAATCGGTTAACCGAATTA
AGGATCCCCGCGGCTCCCTTAGCCATCCGAGTGGACGTGCGTCCTCC
GGCTCGAGGGCCTCGATCAATACCAATCTTGGAAGCGa
GTTCCAATTGGGAATGCCTTCTGAAG
GTCCTTGTAGTCAGCGGCCGCTCCGGAGTCGTTGCGGGTAGCCAAGACG
GCGGCCGCTGACTACAAGGACGACGATGACAAGTAGAGCCGCGAGACATCAACATGC
AGGATCCCCGCGGCTCCCTTA

a

The mutated nucleotides are in bold type.

Foreign genes can be readily introduced and expressed in C.
elegans by methodologies such as microinjection or gene bombardment (21–23). Foreign genetic material is usually preserved as
an extrachromosomal DNA array and can be inherited by the next
generation in a semistable manner (23, 24). Addition of a phenotypic selection marker (either a fluorescent or a behavioral
marker) facilitates the maintenance of animals carrying the extrachromosomal arrays, or alternatively, the plasmids can be stably
integrated into the C. elegans genome by X-ray or gamma ray
irradiation (21). Using this approach, a transgenic Flock House
virus replicon system has been previously created for C. elegans
that supports Flock House virus RNA replication but not viral
capsid assembly or spread (4). This system has been used to identify a role for RNAi in antiviral defense in C. elegans (4, 25), for
transgenerational inheritance of small virus-derived RNAs (26),
and to identify suppressors of RNA silencing (27). More recently,
a transgenic system for generating recombinant Sindbis virus in
Drosophila was described (28), providing the first example of engineering infectious virus particles in a metazoan host.
Here, we describe the first plasmid-based virus reverse genetics
system in C. elegans. By generating transgenic animals that stably
maintain plasmids encoding Orsay virus using standard nematode manipulations, we bypassed the need for traditional cell culture. Viable virus production was demonstrated by de novo infection of C. elegans with viral filtrates produced from the transgenic
animals. In addition to recombinant wild-type Orsay virus, mutant viruses carrying either multiple synonymous mutations or a
FLAG epitope tag fused to the Orsay alpha-delta fusion protein
were generated. This novel reverse genetics system provides a
route to engineer defined mutations in the Orsay genome that will
greatly facilitate studies of both the virus life cycle and its interactions with the host.
MATERIALS AND METHODS
C. elegans strains. Laboratory Caenorhabditis elegans Bristol N2 strain
and the RNAi-deficient mutant rde-1 strain (WM27) were maintained by
feeding with Escherichia coli bacterial strain OP50 at 20°C on nematode
growth medium (NGM) plates (29). Serial passage of both C. elegans N2
and the rde-1 strain was done by transferring 1 cm2 of agar with mixedstage animals onto a fresh OP50-seeded NGM plate.
Plasmid construction. (i) pHIP_RNA1 cloning. The complete Orsay
virus RNA1 segment was cloned into plasmid pPD49.83 driven by a C.
elegans heat shock promoter (30). First, the hepatitis D virus (HDV) ri-
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bozyme sequence (31) was introduced at the 3= end by step extension PCR
with three overlapping primers (Table 1; see also Fig. S1 in the supplemental material). A multistep cloning strategy was used to insert this
fragment into plasmid pPD49.83 as follows. A partial sequence of the heat
shock promoter along with the NsiI site was introduced during step extension PCR amplification and was then cloned into a Topo-TA cloning
vector (Invitrogen). The resulting Topo-RNA1 was digested by NsiI and
XmaI. Two fragments were generated from the Topo-RNA1 genome besides the vector due to the presence of a second NsiI site in the Orsay virus
RNA1 genome. One of the digested fragments flanked by NsiI and XmaI
was subcloned into pPD49.83 vector, which was also digested by NsiI and
XmaI restriction enzymes. The resulting intermediate plasmids were further singly digested by NsiI and ligated to the second delta-NsiI fragment
digested from the aforementioned Topo-RNA1. The orientation of insertion was checked by restriction enzyme digestion and verified by Sanger
sequencing. The final plasmid construct was designated pHIP_RNA1.
(ii) pHIP_RNA2 cloning. HDV ribozyme was introduced at the 3= end
of the Orsay virus RNA2 genome by step extension PCR. A strategy similar
to that for cloning Orsay virus RNA1 was implemented (Table 1; see also
Fig. S1 in the supplemental material). Briefly, part of the heat shock promoter sequence along with the PstI site was introduced into the RNA2
genome by PCR amplification and was then cloned into the Topo-TA
vector (Invitrogen). The resulting Topo-RNA2 was digested by PstI and
BamHI. The pPD49.83 vector was also digested by the two restriction
enzymes PstI and BamHI, and a 335-bp fragment was removed from the
vector, as there are two PstI sites on the vector sequence. Orsay virus
RNA2 with HDV ribozyme and partial promoter sequence digested from
Topo-RNA2 was ligated with pPD49.83 without the 335-bp fragment.
The resulting plasmids were then singly digested by PstI, and the 335-bp
fragment was then inserted. The orientation of insertion was checked by
restriction enzyme digestion and verified by Sanger sequencing. The final
plasmid construct was designated pHIP_RNA2.
(iii) pHIP_RNA1MUT cloning. For generation of a genetic marker in
the Orsay virus genome, a fragment of Orsay virus RNA1 was PCR amplified with a forward primer, RNA1muX, which has the designated mutations (C, C, and T), and a reverse primer, HIPR1R. The PCR product
was further digested with XhoI and XmaI and then ligated into
pHIP_RNA1 digested with the same two restriction enzymes. The final
plasmid was sequence confirmed by Sanger sequencing and was designated pHIP_RNA1MUT.
(iv) pHIP_RNA2FLAG cloning. A sequence encoding a short peptide
linker (SGAAA) followed by the FLAG peptide (DYKDDDDK) was introduced into the 3= end of the alpha-delta coding region of Orsay virus
RNA2 by overlapping PCR. Briefly, a C-terminal 1-kb fragment of the
Orsay virus RNA2 alpha-delta open reading frame (ORF) was generated
by PCR with a forward primer, R2MF, and a reverse primer, R2MR. A 3=
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Primer

Jiang et al.

A

Transcription
start site
...GAAGCC...
5’NC
pHIP

...GGGTCG...
3’NC RZ

RNA1 ORF

Cleavage site
...GGGTCG...
3’NC RZ

RNA2 ORF

NC Virus noncoding region
RZ

HDV ribozyme

pHIP Heat inducible promoter

B
pHIP_RNA1

pHIP_RNA2

pRF4

Microinjection

Heat induction

C

Microinject young adult C. elegans
3~4 days

Pick out transgenic C. elegans
5~7 days

Get stable transgenic C. elegans
3 days

Perform heat induction
2 days

Make virus homogenates

De novo infection on naïve C. elegans

qRT-PCR

IFA

Western blot

FIG 1 Design and work flow of Orsay virus reverse genetics. (A) Design of the
Orsay virus reverse genetics constructs. Orsay virus cDNAs for the entire
RNA1 and RNA2 genome segments were each cloned into a heat-inducible
promoter (pHIP)-driven plasmid and juxtaposed at the 3= end to the selfcleaving hepatitis D virus ribozyme (RZ) to generate pHIP_RNA1 and
pHIP_RNA2, respectively. Arrows indicate the transcription start site and the
ribozyme cleavage site. (B) Experimental strategy of the Orsay virus reverse
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genetics. Recombinant viral plasmids were microinjected into C. elegans to
establish transgenic animals. Viruses were then produced from transgenic animals following heat induction. (C) Work flow describing Orsay virus reverse
genetics. IFA, immunofluorescence assay.
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Transcription
start site
...GAAGCC...
5’NC
pHIP

Cleavage site

fragment of pHIP_RNA2 was generated by PCR amplification with a forward primer, R2FLAGF, which bears the FLAG sequence, and a reverse
primer, HIPR2R. The two fragments were then annealed together and
amplified by primers R2MF and HIPR2R. The resulting fragment was
digested by MfeI and BamHI and then cloned into the pHIP_RNA2 plasmid, which was digested by the same two restriction enzymes. The resulting plasmid is designated pHIP_RNA2FLAG. All primer sequences used
in this study are listed in Table 1.
Microinjection and transgenic lines. One day prior to the microinjection experiment, L4 C. elegans larvae were picked onto a fresh OP50seeded NGM plate. For microinjection, two viral cDNA-carrying plasmids (pHIP_RNA1 and pHIP_RNA2 or mutant forms of these plasmids)
were mixed with the comicroinjection marker plasmid pRF4 (rol-6) (32)
at final concentrations of 50 ng/l, 50 ng/l, and 120 ng/l, respectively.
C. elegans N2 or rde-1 young adults were injected by using a microinjection system (Zeiss). Sets of three microinjected animals were placed on
OP50-seeded 6-cm NGM plates and maintained at 20°C. F1 animals displaying a roller phenotype were individually transferred onto new OP50seeded 6-cm NGM plates 3 to 5 days after injection. F1 plates that produce
F2 roller animals were considered to contain a stable transgenic line. The
stable transgenic lines were maintained and passaged by picking 5 roller
transgenic progeny animals each time onto a new OP50-seeded 6-cm
NGM plate.
Heat induction and transgenic virus filtrate preparation. Heat induction was performed on stable transgenic animals. Five F2 transgenic
roller animals were transferred to a new OP50-seeded 6-cm NGM plate
and maintained for 5 days at 20°C to generate a mixed population. For
heat induction, animals were incubated at 33°C for 2 h and then at 23°C
for 2 days. Animals on each 6-cm NGM plate were harvested by washing
off the plates with 1 ml of M9 buffer, pelleted by spinning at 3,000 rpm for
1 min, and concentrated to 0.5 ml of M9 buffer. The concentrated animals
were resuspended and transferred to a homogenizing tube. Animals were
mixed with 0.5 ml of 1.0-mm silicon beads (zirconia/silica) and then
homogenized by 2 cycles of shaking at 6,000 rpm for 1 min in a tissue
homogenizer (MagNALyzer; Roche) and cooling on ice for 2 min. The
resulting homogenate was centrifuged at maximum speed with a
benchtop Eppendorf centrifuge for 5 min. The supernatant was collected and filtered through a 0.22-m filter (Millipore) and stored at
⫺80°C.
Virus infection and real-time qRT-PCR quantification of virus replication. To quantify Orsay virus production from transgenic C. elegans,
we developed a standard 6-well format infection. Briefly, a synchronized
population of C. elegans embryos was generated by bleaching, which kills
all of the adult animals. Five hundred C. elegans embryos were added per
well of a 6-well plate seeded with a 20-l lawn of OP50 bacteria. Sixteen
hours later, 20 l of transgenic Orsay virus filtrate was added to the bacterial lawn of each well. Infected C. elegans animals were harvested 3 days
after infection. Animals were washed off the plates using 1 ml of M9 buffer
(3 g of KH2PO4, 6 g of Na2HPO4, 5 g of NaCl, 1 ml of 1 M MgSO4, H2O to
1 liter) and then pelleted by centrifugation at 3,000 rpm for 2 min with a
benchtop Eppendorf centrifuge. M9 buffer was removed by pipetting. The
C. elegans pellet was resuspended with 350 l of TRIzol (Invitrogen) and
frozen in liquid nitrogen. RNA extraction and DNase treatment in the
middle of RNA extraction were performed using a Zymo Direct-zol RNA
extraction kit (Zymo Research) by following the manufacturer’s protocol.
RNA was eluted in 30 l of RNase- and DNase-free water. One-step realtime quantitative reverse transcription-PCR (qRT-PCR) was performed
with Orsay virus RNA1 or RNA2 probe in a 1:100 dilution of viral RNA as
described previously (3).

7

N2

5

150
100
75

4

50

3

37

Capsid

2

25

N/
D

1
0

Mock

20

rec-WT

nat-WT

C

Mock

rec-WT

nat-WT

FIG 2 De novo infection of C. elegans by virus produced from transgenic animals. (A) Real-time qRT-PCR quantification of both recombinant wild-type Orsay
virus (rec-WT) and naturally occurring Orsay virus (nat-WT) replication in C. elegans N2 and rde-1 strains. A nontransgenic C. elegans N2 preparation was used
as a mock control. N/D, viral RNA was not detected. Error bars indicate standard deviations from three independent infection experiments. (B) Western blot with
anti-Orsay virus capsid antibody. Arrow indicates the virus capsid band. (C) Immunofluorescence staining of recombinant and natural Orsay virus replication
in infected C. elegans with anti-Orsay virus capsid antibody. Arrows indicate the infected intestinal cells. Scale bars represent 20 m.

Western blotting. C. elegans was infected with transgenic filtrate as
described above. The infected animals in a 6-well plate were passaged to
expand by transferring 1 cm2 of agar to a 10-cm NGM plate seeded with
OP50. Approaching starvation, infected C. elegans animals were harvested
and homogenized. Western blotting was performed as previously described (3). Briefly, the infected homogenates were mixed with 6⫻ sample
loading buffer (0.35 M Tris-HCl, 10% SDS, 0.6 M dithiothreitol [DTT],
0.012% bromphenol blue, 30% glycerol) and boiled for 5 min. Protein
samples were loaded into an 8.6-cm-long precast SDS-PAGE gel (Any kD
Mini-PROTEAN TGX gel; Bio-Rad), and the gel was run at 30 mA for 1 h.
Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Invitrogen) and blotted with specific viral capsid peptide-derived
antibody.
Immunofluorescence assay. (i) Epifluorescence analysis of rec-WT
and nat-WT infection (see Fig. 2). Immunofluorescence staining for Orsay virus capsid was performed as described before (33). The initial recombinant wild type Orsay virus (rec-WT)-infected and the natural Orsay
virus (nat-WT)-infected rde-1 animals were passaged by transfer from a
6-well NGM plate to a 10-cm OP50-seeded NGM plate. After 4 days, the
infected C. elegans animals were fixed in Bouin’s fixative and quickly frozen in liquid nitrogen. Immunofluorescence staining was performed by
incubation with a rabbit anti-capsid primary antibody followed by Alexa
Fluor 488-labeled goat anti-rabbit secondary antibody (Invitrogen). Images for epifluorescence were acquired with a Zeiss Axioskop Mot Plus
fluorescence microscope.

TABLE 2 Transgenic C. elegans strains generated in this study
Construct

Strain name or
genotype

No. of transgenic
strains

No. of virusproducing strains

rec-WT1
rec-WT2
rec-MUT
rec-FLAG

N2
N2
N2
rde-1

3
4
7
5

1
3
3
1
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(ii) Confocal microscopy of rec-FLAG and rec-WT infection (see
Fig. 4). rde-1 animals were synchronized by bleaching, and 2,000 embryos
were seeded in each well of a 6-well plate with a 20 l of an OP50 bacterial
lawn. C. elegans animals were infected 16 h later with 20 l of rec-WT or
recombinant FLAG-tagged Orsay virus (rec-FLAG) virus filtrate prepared
as described above. Twenty-four hours after infection, the infected C.
elegans animals were fixed with Bouin’s fixative and frozen in liquid nitrogen. Double immunofluorescence staining was performed with an anti-FLAG M2 monoclonal antibody (Sigma) and viral protein-specific antibodies (rabbit-derived anti-capsid antibody or anti-delta antibody).
Secondary antibodies were Alexa Fluor 488-labeled goat anti-mouse antibody or Alexa Fluor 568-labeled goat anti-rabbit antibody (Invitrogen).
Nuclear staining was performed with TO-PRO3 (Invitrogen) for 20 min.
Confocal images were acquired with a Zeiss LSM510 Meta laser scanning
confocal microscope (Carl Zeiss Inc., Thornwood, NY).

RESULTS AND DISCUSSION

Experimental strategy for development of Orsay virus reverse
genetics. The overall strategy for generating recombinant Orsay
virus entailed engineering plasmids that contain cDNAs of Orsay
virus RNA1 and RNA2 and then microinjecting the plasmids together to create transgenic animals harboring extrachromosomal
arrays of the two plasmids, which should then initiate host cell
transcription from the plasmids. In theory, translation of the DNA
templated transcripts would lead to expression of the Orsay virus
RdRP, which would then trigger authentic viral replication and
subsequent capsid expression and viral packaging. To evaluate the
production of viable virus, the animals were then homogenized
and filtered through a 0.22-m membrane; the resulting filtrate
was then used for de novo infection of naive animals and subsequently assayed by qRT-PCR, Western blotting, or immunofluorescence assay (Fig. 1).
Specifically, cDNA sequences of the Orsay virus RNA1 and
RNA2 were cloned into a C. elegans expression vector driven by a
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A
pHIP

B

5’NC

RNA1 ORF

3’NC RZ

Amino acid:

585 G-586 L-587 D

Nucleotides:

GGC C T CG A T
RT-PCR

re
c-M
UT
1
re
c-M
UT
2
re
c-M
UT
3
re
c-M
UT
1
re
c-M
UT
2
re
c-M
UT
3

PCR

M

***

2000

600

100

C

1.......10........20........30.....

WT GCCTACAGGCTCGAGGGACTAGACCAATACCAATC
rec-MUT1 GCCTACAGGCTCGAGGGCCTCGATCAATACCAATC
rec-MUT2 GCCTACAGGCTCGAGGGCCTCGATCAATACCAATC
rec-MUT3 GCCTACAGGCTCGAGGGCCTCGATCAATACCAATC

rec-MUT1

rec-MUT2

rec-MUT3
FIG 3 Introduction of a genetic marker into the Orsay virus genome. (A)
Design of an Orsay virus genetic marker in its RNA1 genome segment. Arrows
indicate the position where primers were used to perform RT-PCR. Letters in
green highlight the three synonymous point mutations introduced, with asterisks indicating their positions in the genome. (B) RT-PCR and PCR spanning
the mutated locus. RNA was extracted from three C. elegans cultures infected
by three independent mutant virus filtrates. The expected PCR band is ⬃600
bp. M, molecular size marker. (C) The genetic marker was preserved in the
recombinant virus as shown by the Sanger sequencing chromatogram of the
three mutant viruses. Aligned boxes indicate the genetic marker.

(rec-MUT1, rec-MUT2, and rec-MUT3) produced from three independent transgenic strains showed levels of replication similar
to that with rec-WT infection in the rde-1 strain (data not shown).
Confirming that these viruses were recombinant in origin, RTPCR of RNA extracted from the de novo-infected rde-1 C. elegans
generated the expected band (Fig. 3B), and sequencing of the amplicon yielded the three synonymous mutations (Fig. 3C). As a
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heat-inducible promoter. One reason we chose this promoter is
that it is known to be preferentially active in the C. elegans pharyngeal and intestinal tissue (30), which coincides with the Orsay
virus in vivo tissue tropism (33). Prior studies that developed cell
culture-based reverse genetics systems for influenza A virus and
Pariacoto virus, an insect nodavirus, demonstrated the strict requirement for maintaining authentic termini of the genome segments for optimal viral replication (10, 11, 16). Therefore, we
introduced a hepatitis D virus ribozyme at the 3= end of the RNA1
segment, and at the 5= end, the Orsay virus cDNA was cloned
immediately 3= to the heat-inducible promoter transcriptional
start site (Fig. 1A). The transcript produced from this construct
following ribozyme cleavage should, in theory, be identical in sequence to authentic Orsay virus genomic RNAs.
Wild-type Orsay virus produced from transgenic C. elegans
is infectious. To demonstrate that the transgenic C. elegans reverse genetics system works in principle, we focused first on
generating recombinant wild-type Orsay virus. Plasmids
pHIP_RNA1 and pHIP_RNA2 were microinjected along with
pRF4, a “roller” phenotypic marker plasmid, and three stable F2
transgenic animals were identified by screening for the roller phenotype. The stable transgenic animals were then heat shocked to
induce the expression of Orsay virus RNA. Two days post-heat
shock, expression of both Orsay virus RNA1 and RNA2 was detected by real-time qRT-PCR in all three lines (data not shown).
Virus filtrates were generated from each of these lines, and
following infection of N2 and rde-1 strains of C. elegans, one of the
three filtrates yielded viable virus that behaved as natural Orsay
virus (nat-WT). By qRT-PCR, the recombinant wild-type Orsay
virus (rec-WT) produced from transgenic animals replicated to
higher levels in the RNAi-deficient C. elegans rde-1 strain than in
the N2 strain, as seen with natural nat-WT infection (Fig. 2A).
Patterns of viral capsid protein expression as assessed by both
Western blotting (Fig. 2B) and immunofluorescence assay (Fig.
2C) were similar for both natural and recombinant Orsay virus. In
a second independent experiment, three out of four stable transgenic strains that we generated produced recombinant wild-type
Orsay virus (Table 2). Overall, the process of microinjection and
identification of progeny producing virus requires about 15 days.
To evaluate the stability of virus production in the transgenic
C. elegans harboring pHIP_RNA1 and pHIP_RNA2, we conducted 7 serial passages of the transgenic strain. Filtrates generated
following heat induction of passages 5, 6, and 7 each contained
viable virus as defined by de novo infection and qRT-PCR (see Fig.
S2A in the supplemental material). In addition, an aliquot of the
F4 that had been frozen in a ⫺80°C freezer, upon revival and heat
shock of its F5 progeny, also yielded viable virus (see Fig. S2A).
These results demonstrate the generation of recombinant wildtype Orsay virus through a plasmid-based reverse genetics system
in the metazoan host C. elegans and the stability of the transgenic
strains.
A genetic marker can be introduced into Orsay virus genome
by reverse genetics. We next created a plasmid containing a series
of three synonymous point mutations that were in the wobble
position of three consecutive codons (pHIP-RNA1MUT) in the
middle of the Orsay virus RdRP to demonstrate that recombinant
viruses with defined mutations could be generated (Fig. 3A).
Transgenic C. elegans strains were created by microinjecting
pHIP_RNA1MUT and pHIP_RNA2, and viral filtrates were prepared as before. Infection of the rde-1 strain with mutant viruses

Reverse Genetics for Orsay Virus in C. elegans

Translation

-W

T

AG

T

-F
L
re
c

-W

FLAG 3’NC RZ

re
c

-F
L

RNA2 ORF

re
c

5’NC

M

pHIP

RT-PCR

AG

PCR

...TCCGGAGCGGCCGCTGACTACAAGGACGACGATGACAAGTAG

re
c

B

A

2000

alpha
SGAAADYKDDDDK#

600

FLAG

100

Delta

Capsid

Merge

FLAG

Capsid

Merge

rec-WT

C

E
FLAG

Delta

Merge

rec-WT

rec-FLAG

D

FIG 4 Generation and verification of a FLAG epitope-tagged Orsay virus. (A) A schematic design of FLAG-tagged Orsay virus RNA2 genome segment.
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control, PCR amplification in the absence of RT yielded no bands
(Fig. 3B), eliminating any possibility of residual carryover of
pHIP_RNA1MUT plasmid from the transgenic animal filtrate
(Fig. 3B). Furthermore, serial passage of the rec-MUT virus-infected animals showed the presence of the three synonymous mutations in the recombinant virus genome at the third passage by
sequencing (data not shown). These results clearly demonstrate
the ability to generate mutants in the Orsay virus genome using
this plasmid-based reverse genetics system.
Generation of a FLAG epitope-tagged Orsay virus by reverse genetics. To further demonstrate the feasibility of genetic
engineering of Orsay virus, we next created a plasmid
(pHIP_RNA2FLAG) that encoded an epitope tag (FLAG: DYKD
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DDDK) with a 5-amino-acid linker sequence, SGAAA (Fig. 4A).
We have previously demonstrated that the Orsay virus RNA2 segment encodes the capsid protein (alpha) and an alpha-delta fusion
protein of unknown function that is expressed by a ribosomal
frameshifting mechanism (3). Thus, the FLAG tag was designed to
be expressed at the C terminus of the alpha-delta fusion protein
(Fig. 4A). Following generation of transgenic animals and virus
filtrate preparation, de novo infection of rde-1 C. elegans demonstrated replication of the FLAG-tagged Orsay virus (data not
shown). RT-PCR primers that span the FLAG sequence insertion
site were designed. A band with higher molecular weight was obtained with RNA extracted from rec-FLAG-infected animals than
with RNA from the corresponding rec-WT-infected C. elegans
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ditis nematode-infecting viruses, Le Blanc and Santeuil viruses
(2). As both of those viruses have the opposite host specificity of
Orsay virus (i.e., they can infect Caenorhabditis briggsae but not C.
elegans), the availability of reverse genetics would enable the creation of reassortant or chimeric viruses that could then be used to
explore viral and host factors that govern infection specificity. To
conclude, the Orsay virus reverse genetics system developed in this
work will greatly facilitate studies of Orsay virus and its interactions with its host, C. elegans.
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loss of the FLAG sequence or reversion to wild type was observed
during this time frame (see Fig. S2B in the supplemental material;
other data not shown).
In summary, we have demonstrated the feasibility of using a
transgenic C. elegans-based reverse genetics system to generate
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virus expression to specific tissues, as has recently been described
for Drosophila with modified Sindbis virus (28). The successful
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